Drug intelligence / Profile preview

samhovir

Development stage: Preclinical
Lead developer: Luckwel Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

Samhovir (LWEL-2103) is an investigational antiviral drug being developed by Luckwel Pharmaceuticals for the treatment of COVID-19. As of late 2021, the program was in the IND-enabling or preclinical stage of development. While specific details regarding its mechanism of action or chemical structure have not been publicly disclosed, it is part of Luckwel's portfolio of COVID-19 therapeutics alongside other candidates like Vikonra (LWEL-2120) and Telfovia (LWEL-2119). The drug is likely a small molecule antiviral agent intended for oral administration, consistent with the developer's focus on specialty chemical and pharmaceutical manufacturing.

Brand names: Samhovir
Other names: LWEL-2103LWEL2103LWEL 2103

Beyond the preview

Go deeper on samhovir.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on samhovir.

Explore the full profile